These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


265 related items for PubMed ID: 11042654

  • 1. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
    Jantunen E, Mahlamäki E, Nousiainen T.
    Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
    [Abstract] [Full Text] [Related]

  • 2. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK, Lee J, Kim MW, Park CJ, Chi HS, Huh J, Kim SH, Suh C.
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [Abstract] [Full Text] [Related]

  • 3. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution.
    Magagnoli M, Castagna L, Balzarotti M, Sarina B, Timofeeva I, Bertuzzi A, Compasso S, Nozza A, Siracusano L, Santoro A.
    Am J Hematol; 2003 Aug; 73(4):267-72. PubMed ID: 12879431
    [Abstract] [Full Text] [Related]

  • 4. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M.
    Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
    [Abstract] [Full Text] [Related]

  • 5. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G.
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [Abstract] [Full Text] [Related]

  • 6. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
    Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD.
    Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
    [Abstract] [Full Text] [Related]

  • 7. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD.
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [Abstract] [Full Text] [Related]

  • 8. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW, Seftel MD, Rubinger M, Szwajcer D, Demers A, Nugent Z, Schroeder G, Butler JB, Cooke A.
    Int J Radiat Oncol Biol Phys; 2010 Oct 01; 78(2):513-20. PubMed ID: 20137862
    [Abstract] [Full Text] [Related]

  • 9. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH, Schwartzberg L, Li W, Hazelton B, West W.
    Bone Marrow Transplant; 1996 May 01; 17(5):715-21. PubMed ID: 8733687
    [Abstract] [Full Text] [Related]

  • 10. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
    Moreau P, Milpied N, Voillat L, Colombat P, Mahé B, Rapp MJ, Moreau A, Dupas B, Bulabois CE, Juge-Morineau N, Harousseau JL.
    Bone Marrow Transplant; 1998 Jun 01; 21(12):1193-6. PubMed ID: 9674850
    [Abstract] [Full Text] [Related]

  • 11. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R.
    Bone Marrow Transplant; 1997 Mar 01; 19(6):529-37. PubMed ID: 9181898
    [Abstract] [Full Text] [Related]

  • 12. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
    Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C.
    Ann Hematol; 2008 Jan 01; 87(1):43-8. PubMed ID: 17710401
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study].
    Kitajima H, Nasu K, Tsudo M, Fujimoto M, Hayashi K, Ohno H, Konaka Y, Katsurada T, Arima N, Doi S, Moriguchi T, Fukuhara S.
    Rinsho Ketsueki; 2001 Mar 01; 42(3):191-8. PubMed ID: 11345781
    [Abstract] [Full Text] [Related]

  • 16. [A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].
    Chou T, Ishiguro T, Imajo K, Kawano F, Gondo H, Kasai M, Masuda M, Koike M, Shimazaki C, Hara M, Shinagawa K, Ogawa M, Takaku F, Harada M.
    Rinsho Ketsueki; 1999 Oct 01; 40(10):1058-67. PubMed ID: 10565222
    [Abstract] [Full Text] [Related]

  • 17. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedè P, Bondesan P, Magni M, Matteucci P, Gallamini A, Pileri A, Gianni AM.
    Bone Marrow Transplant; 2002 Dec 01; 30(11):725-32. PubMed ID: 12439694
    [Abstract] [Full Text] [Related]

  • 18. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
    Seropian S, Nadkarni R, Jillella AP, Salloum E, Burtness B, Hu GL, Zelterman D, Cooper DL.
    Bone Marrow Transplant; 1999 Mar 01; 23(6):599-605. PubMed ID: 10217191
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
    Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L, Sánchez-Cortés E, Ayala-Sánchez M, Guevara-Moreno ME, García-León LD, Rosas-Cabral A, Esparza MA, González-Llaven J.
    Bone Marrow Transplant; 2000 Jun 01; 25(11):1141-6. PubMed ID: 10849526
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 14.